Intel stock spikes after report of possible US government stake
Investing.com - InMed Pharmaceuticals reported on Friday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
InMed Pharmaceuticals announced earnings per share of $-4.060 on revenue of $320.79K. Analysts polled by Investing.com EPS of $-4.250 on revenue of $500K.
InMed Pharmaceuticals 's are down 90% and is trading at $3.000 , still down 94.94% from its 52 week high of $59.25 set on Wednesday, November 17, 2021.
InMed Pharmaceuticals follows other major Healthcare sector earnings this month
InMed Pharmaceuticals's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar